Vea MedIQ en Español
Neste vídeo, Dr. Douglas Kazutoshi Sato, médico neurologista, professor da Escola de Medicina da PUCRS e diretor do Instituto de Geriatria e Gerontologia da PUCRS, comenta sobre alguns trabalhos que foram apresentados na Reunião Anual do AAN 2022, abordando temas importantes da neuroimunologia.
Destaques em neuroimunologia da Reunião Anual do AAN
Escrito por: Zilda Machado Meneghelo em 28 de abril de 2022
1 min de leitura
Referências
Cassandre Landes-Château et al., Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome. Presented at 2022 AAN Annual Meeting.
Maria A. Rocca et al., Spinal Cord Lesions and Brain Grey Matter Atrophy Independently Predict Clinical Worsening in Multiple Sclerosis: A 5-Year, Multicentre Study. Presented at 2022 AAN Annual Meeting.
John Foley et al., Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6‑Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis. Presented at 2022 AAN Annual Meeting.
James F. Howard et al., Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Open-label Extension. Presented at 2022 AAN Annual Meeting.
